News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Webinars
Exciting lectures and practical application tips via video, whenever you want: Our on-demand webinars make it possible. Make yourself comfortable and click play.
Selected webinars
Webinars of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
06-Apr-2016 - MorphoSys AG announced that it filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. This patent, which is owned by MorphoSys, describes and claims antibodies with particular ...
Milestone triggered by first commercial sale of DARZALEX in the United States
23-Nov-2015 - Genmab A/S announced it has achieved a USD 45 million milestone in its DARZALEX™ (daratumumab) collaboration with Janssen Biotech, Inc. The milestone payment was triggered by the first commercial sale of DARZALEX in the United States. "Today marks a significant moment in the history of Genmab - ...
29-Sep-2015 - Genmab A/S announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted accelerated assessment to the Marketing Authorization Application (MAA) for daratumumab.The MAA is for daratumumab as a treatment for patients with relapsed and ...
29-Apr-2015 - Genmab A/S announced that the top-line results from the Phase III COMPLEMENT 2 study showed that treatment with Arzerra® (ofatumumab) plus fludarabine and cyclophosphamide met the primary endpoint of improved progression-free survival (PFS) in patients with relapsed CLL (p = 0.0036) compared to ...
20-Mar-2015 - Genmab A/S announced that its subsidiary Genmab Holding B.V. entered into an agreement to purchase antibodies and related patents and know-how from iDD Biotech SAS. The pre-clinical stage antibodies are directed to DR5, also known as Trail Receptor 2 (TRAIL-R2), an emerging cancer target. ...
23-Feb-2015 - Genmab A/S announced it has entered a co-development and commercialization agreement with BioNovion to evaluate a number of DuoBody product candidates targeting immune checkpoints. Genmab and BioNovion will contribute panels of antibodies for the creation of bispecific antibody products using ...
05-Feb-2015 - Genmab A/S announced preliminary results from the Phase II study of daratumumab in double refractory multiple myeloma conducted by its collaboration partner Janssen Biotech, Inc. (Janssen). The overall response rate (ORR) in the study was 29.2% in the 16 mg/kg dosing group and the median ...
05-Dec-2014 - Genmab A/S announced that its collaboration partner, Janssen Biotech, Inc. (Janssen) plans to start a Phase II study of daratumumab in non-Hodgkin’s lymphomas (NHL). The study (LYM2001) will evaluate daratumumab monotherapy in three different types of NHL, diffuse large B-cell lymphoma (DLBCL), ...
12-Nov-2014 - Genmab A/S announced that the French Intergroup of Myeloma (IFM) in collaboration with Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen Biotech, Inc. (Janssen) plans to start an additional Phase III study of daratumumab in frontline multiple myeloma. The study ...
GSK enters patent settlement with Genentech regarding ofatumumab
28-Mar-2012 - Genmab A/S announced that GlaxoSmithKline (GSK) has agreed a settlement with Genentech Inc. and City of Hope (a California not-for-profit organization) concerning two U.S. patents that relate to recombinant antibody production for ofatumumab. GSK is Genmab’s development and commercial ...
© 1997-2024 LUMITOS AG, All rights reserved